Mezzasalma Advisors LLC Has $2.63 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Mezzasalma Advisors LLC lowered its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.3% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,500 shares of the biopharmaceutical company’s stock after selling 33 shares during the period. Regeneron Pharmaceuticals comprises about 1.1% of Mezzasalma Advisors LLC’s portfolio, making the stock its 27th biggest holding. Mezzasalma Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $2,628,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of REGN. Atria Wealth Solutions Inc. raised its holdings in Regeneron Pharmaceuticals by 12.4% during the 4th quarter. Atria Wealth Solutions Inc. now owns 1,971 shares of the biopharmaceutical company’s stock valued at $1,731,000 after buying an additional 218 shares during the last quarter. Gilbert & Cook Inc. increased its position in Regeneron Pharmaceuticals by 8.3% during the fourth quarter. Gilbert & Cook Inc. now owns 1,907 shares of the biopharmaceutical company’s stock valued at $1,675,000 after acquiring an additional 146 shares during the last quarter. Choreo LLC bought a new position in Regeneron Pharmaceuticals in the fourth quarter worth approximately $920,000. Kestra Private Wealth Services LLC raised its stake in shares of Regeneron Pharmaceuticals by 19.7% in the fourth quarter. Kestra Private Wealth Services LLC now owns 1,772 shares of the biopharmaceutical company’s stock worth $1,556,000 after buying an additional 292 shares during the period. Finally, Norden Group LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth $230,000. 83.31% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In related news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Bonnie L. Bassler sold 827 shares of the stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $1,011.00, for a total transaction of $836,097.00. Following the completion of the sale, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,397,202. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 22,239 shares of company stock valued at $23,933,880. 7.48% of the stock is owned by insiders.

Regeneron Pharmaceuticals Stock Up 0.5 %

Shares of REGN traded up $5.76 during trading hours on Friday, hitting $1,184.69. 405,354 shares of the company were exchanged, compared to its average volume of 467,334. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.62 and a current ratio of 5.44. The firm’s 50 day moving average is $1,100.29 and its 200-day moving average is $1,010.55. The company has a market cap of $130.54 billion, a PE ratio of 35.00, a PEG ratio of 3.12 and a beta of 0.13. Regeneron Pharmaceuticals, Inc. has a 52 week low of $769.19 and a 52 week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating the consensus estimate of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. During the same quarter in the prior year, the firm earned $8.79 earnings per share. The business’s quarterly revenue was up 12.3% on a year-over-year basis. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on REGN. Evercore ISI assumed coverage on Regeneron Pharmaceuticals in a report on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 price target on the stock. JPMorgan Chase & Co. boosted their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Morgan Stanley cut their price objective on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Wells Fargo & Company lifted their price objective on Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Finally, Guggenheim upped their price objective on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $1,108.45.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.